Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of ankylosing spondylitis patient safety and efficacy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chung Shan Medical University
• Treatments: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Golimumab; Sulfasalazine

Criteria

Inclusion Criteria:

• Age ≥18 years old

• HLA B27 positive

• X ray examination

• Clinical symptoms and physical examination, the following three conditions are subject to at least two:

i.lower back pain and morning stiffness symptoms persist more than 3 months ii. lumbar activity is restricted iii. chest expansion is restricted

• Active disease for four weeks or more (continue two examination BASDAI>6, ESR> 28 mm/1 hr and CRP>1 mg/dl)

Exclusion Criteria:

• pregnant or breast-feeding women

• patients with active infections

• highly infectious patients

• Cancer or precancerous condition of the patient

• multiple sclerosis